Cell & Gene The Podcast Videocast

  1. Best Practices For Partnering With A CDMO 8/9/2022

    Emily Moran, VP of Vector Manufacturing and Avi Nandi, VP of Process Development at the Center for Breakthrough Medicines share key considerations on Cell & Gene: The Podcast for biotechs looking to partner with a CDMO. Learn how to reduce risk, lower costs, and better manage expectations when it comes the biotech/CDMO relationship.

  2. Restoration of Immune Balance with Anish Suri, Ph.D., President and CSO at Cue Biopharma 3/2/2022

    Cue Biopharma's Anish Suri, Ph.D., explains why the clinical-stage biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body to transform the treatment of cancer.

  3. Gene Therapies For Spinal Cord-Related Disorders With SwanBio's CSO 9/16/2021

    Karen Kozarsky, Ph.D., Co-Founder and CSO of SwanBio explains how the company is pioneering a deep and varied pipeline of gene therapies for genetically defined neurological diseases with a focus on the spinal cord.

  4. Hospital Systems & Complex Therapies With University Of Pennsylvania Health System's Kevin Mahoney 8/20/2021

    On this episode of Cell & Gene: The Podcast, University of Pennsylvania Health System’s CEO Kevin Mahoney talks to Host Erin Harris about how hospital systems must evolve to meet the needs of cell and gene therapy patients as these complex therapies are commercialized. They discuss what comprises UPHS and the ongoing innovation it brings to advanced therapies as well as how the Health System stays patient-focused at all costs.

  5. State-of-the-Art GMP Manufacturing RNA Cell Therapies With Cartesian's CEO 8/19/2021

    Dr. Murat Kalayoglu, CEO at Cartesian Therapeutics, details the cell and gene therapy sector's advancements in RNA cell therapy and the why behind the company's decision to build its own wholly-owned GMP manufacturing facility.

  6. The Future of Tissue-Based Therapies 7/8/2021

    Enzyvant's CEO, Rachelle Jacques, explains the company's lead asset, the roadmap for tissue-based therapies, and more.